LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Lineage Cell Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.95−0.03 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $249.13M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.6972 (−42.25%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Lineage Cell Therapeutics, Inc. grew revenue 19.9% to $13.08M over the twelve months to Jun 30, 2026. Free cash flow was -$24.39M.
Revenue
$13.08M
+19.9% vs. a year earlier
Operating income
-$26.85M
TTM Q2 2026
Free cash flow
-$24.39M
TTM Q2 2026
EPS, diluted
-$0.19
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $249.13M
- P/E ratio
- –
- Price to sales
- 19.04
- Price to book
- 4.09
- Dividend yield
- –
- Free cash flow yield
- -9.79%
Fundamentals
- Revenue
- $13.08M
- Net income
- -$32.26M
- EPS, diluted
- -$0.19
- Free cash flow
- -$24.39M
- Book value per share
- $0.23
- Diluted shares
- 261M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$13.08M+19.9% YoY
Gross profit
–
Operating income
-$26.85M
Net income
-$32.26M
EPS, diluted
-$0.19
Free cash flow
-$24.39M
Reported periodTrailing twelve months